Literature DB >> 21658659

Cytopenia, dysplasia, and monocytosis: a precursor to chronic myelomonocytic leukemia or a distinct subgroup? Case reports and review of literature.

Zeba N Singh1, Ginell R Post, Elias Kiwan, Anne-Marie Maddox.   

Abstract

Chronic myelomonocytic leukemia (CMML) consists of disorders with overlapping dysplastic and proliferative features. The diagnosis of CMML requires absolute monocytosis (> 1000/μL) in addition to other criteria outlined by the World Health Organization (WHO) classification.(1) Monocytosis not reaching 1000/μL has been observed in myelodysplastic syndrome (MDS) and presents a diagnostic challenge in classification especially if increases in leukocyte count occurring during disease shifts the monocyte count into the absolute range. We discuss the laboratory and clinical features of 3 patients with myelodysplasia and associated monocytosis. Absolute neutropenia was the dominant feature at presentation, with mild anemia, thrombocytopenia, monocytosis (as a percentage), multilineage dysplasia, and increased myeloblasts, consistent with a diagnosis of refractory anemia with excess blasts (RAEB). Absolute monocytosis fulfilling the diagnostic criteria for CMML developed over 6-8 months, prompting a change in diagnosis. Two of 3 patients had normal cytogenetic examinations. JAK2 V617F mutation was detected after transformation to CMML in 1 of them; in the other, a novel translocation t(5;12)(p13;q24) was observed at the time of progression to acute leukemia. The use of different diagnostic terminologies--MDS, dysplasia with reactive monocytosis, myeloproliferative, and myeloproliferative/myelodysplastic syndromes by different and even the same pathologists at different times created confusion among the clinicians and patients. The disease course in these 3 patients was characterized by better survival and prolonged time to progression to acute leukemia, than predicted based on the original diagnosis of RAEB, suggesting that MDS with monocytosis may represent a subgroup distinct from MDS or CMML.
Copyright © 2011. Published by Elsevier Inc.

Entities:  

Mesh:

Year:  2011        PMID: 21658659     DOI: 10.1016/j.clml.2011.03.019

Source DB:  PubMed          Journal:  Clin Lymphoma Myeloma Leuk        ISSN: 2152-2669


  4 in total

1.  Progression, transformation, and unusual manifestations of myelodysplastic syndromes and myelodysplastic-myeloproliferative neoplasms: lessons learned from the XIV European Bone Marrow Working Group Course 2019.

Authors:  Konnie Hebeda; Ludmila Boudova; Christine Beham-Schmid; Attilio Orazi; Hans-Michael Kvasnicka; Umberto Gianelli; Alexandar Tzankov
Journal:  Ann Hematol       Date:  2020-10-31       Impact factor: 3.673

2.  Evolution of chronic myelomonocytic leukemia from refractory anemia: the unusual course of a myelodysplastic syndrome.

Authors:  Pasquale Niscola; Andrea Tendas; Laura Scaramucci; Marco Giovannini; Stefano Fratoni; Paolo de Fabritiis
Journal:  Blood Res       Date:  2013-06-25

Review 3.  Proposed diagnostic criteria for classical chronic myelomonocytic leukemia (CMML), CMML variants and pre-CMML conditions.

Authors:  Peter Valent; Attilio Orazi; Michael R Savona; Mrinal M Patnaik; Francesco Onida; Arjan A van de Loosdrecht; Detlef Haase; Torsten Haferlach; Chiara Elena; Lisa Pleyer; Wolfgang Kern; Tea Pemovska; Gregory I Vladimer; Julie Schanz; Alexandra Keller; Michael Lübbert; Thomas Lion; Karl Sotlar; Andreas Reiter; Theo De Witte; Michael Pfeilstöcker; Klaus Geissler; Eric Padron; Michael Deininger; Alberto Orfao; Hans-Peter Horny; Peter L Greenberg; Daniel A Arber; Luca Malcovati; John M Bennett
Journal:  Haematologica       Date:  2019-05-02       Impact factor: 9.941

4.  Myelodysplastic syndrome transforming to atypical chronic myeloid leukemia shows changes in its mutation allele frequency and acquisition of new mutations.

Authors:  Hakim Nm; Tam W; Philipovskiy A; Tonk V; Orazi A
Journal:  Leuk Res Rep       Date:  2021-05-18
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.